Evidence map›Paper›PMID 31744501›Full record

ArticleBMC complementary and alternative medicine2019

Protective effect of Shenmai injection on doxorubicin-induced cardiotoxicity via regulation of inflammatory mediators.

Sheng Zhang, Zhen-Qiang You, Lin Yang, Li-Li Li, You-Ping Wu, Li-Qiang Gu, Yan-Fei Xin

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Pretreatment with Shenmai Injection Protects against Coronary Microvascular Dysfunction.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  12. Article
  13. Oxidative medicine and cellular longevity · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sheng ZhangCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China.
Zhen-Qiang YouCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China.
Lin YangCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China.
Li-Li LiCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China.
You-Ping WuThe Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Li-Qiang GuCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China.
Yan-Fei XinCenter of Safety Evaluation, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou, 310013, Zhejiang, China. xinyanfei@gmail.com.
Zhejiang Academy of Medical Sciences · CNChildren's Hospital of Zhejiang University · CNZhejiang University of Technology · CN

Funding

The Natural Sciences Foundation of Zhejiang LQY18H160001The Natural Sciences Foundation of Zhejiang LQY19H280002The Natural Sciences Foundation of Zhejiang LY17H310009Zhejiang Provincial Bureau of Traditional Chinese Medicine 2019ZB020Zhejiang Provincial Bureau of Traditional Chinese Medicine t 2019ZB019Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents 00000000
6 · The paper itself

Abstract

backgroundDoxorubicin (DOX) is a chemotherapy drug for malignant tumors. The clinical application of DOX is limited due to its dosage relative cardiotoxicity. Oxidative damage and cardiac inflammation appear to be involved in DOX-related cardiotoxicity. Shenmai injection (SMI), which mainly consists of Panax ginsengC.A.Mey.and Ophiopogon japonicus (Thunb.) Ker Gawl, is widely used for the treatment of atherosclerotic coronary heart disease and viral myocarditis in China. In this study, we investigated the protective effect of Shenmai injection on doxorubicin-induced acute cardiac injury via the regulation of inflammatory mediators.

methodsMale ICR mice were randomly divided into seven groups: control, DOX (10 mg/kg), SMI (5 g/kg), DOX with pretreatment with SMI (0.5 g/kg, 1.5 g/kg or 5 g/kg) and DOX with post-treatment with SMI (5 g/kg). Forty-eight hours after the last DOX administration, all mice were anesthetized for ultrasound echocardiography. Then, serum was collected for biochemical and inflammatory cytokine detection, and heart tissue was collected for histological and Western blot detection.

resultsA cumulative dose of DOX (10 mg/kg) induced acute cardiotoxicity in mice manifested by altered echocardiographic outcome, and increased tumor necrosis factor, interleukin 6 (IL-6), monocyte chemotactic protein 1, interferon-γ, and serum AST and LDH levels, as well as cardiac cytoplasmic vacuolation and myofibrillar disarrangement. DOX also caused the increase in the expression of IKK-α and iNOS and produced a large amount of NO, resulting in the accumulation of nitrotyrosine in the heart tissue. Pretreatment with SMI elicited a dose-dependent cardioprotective effect in DOX-dosed mice as evidenced by the normalization of serum inflammatory mediators, as well as improve dcardiac function and myofibril disarrangement.

conclusionsSMI could recover inflammatory cytokine levels and suppress the expression of IKK-α and iNOS in vivo, which was increased by DOX. Overall, there was evidence that SMI could ameliorate DOX-induced cardiotoxicity by inhibiting inflammation and recovering heart dysfunction.

Indexed as

AnimalsAntineoplastic AgentsCardiotoxicityDoxorubicinDrugs, Chinese HerbalHeartHumansInflammation MediatorsInterleukin-6MaleMiceMice, Inbred ICROphiopogonPanaxTumor Necrosis Factor-alphaAntineoplastic AgentsDoxorubicinDrugs, Chinese HerbalInflammation MediatorsInterleukin-6Tumor Necrosis Factor-alphaAnti-inflammatoryCardiotoxicityDoxorubicinShenmai injection

Identifiers

PMID31744501
PMCPMC6862794
OpenAlexW2989965365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.